We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+79.02%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
+$281M
Cap. Flow
-$93.3M
Cap. Flow %
-6.73%
Top 10 Hldgs %
66.46%
Holding
81
New
10
Increased
14
Reduced
17
Closed
22

Top Buys

Rank Stock Value
1
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$37.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27M
3
MRK icon
Merck
MRK
+$20.7M
4
BIIB icon
Biogen
BIIB
+$17.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.7M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$26.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
4
AGN
Allergan plc
AGN
+$22.6M
5
AMGN icon
Amgen
AMGN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 94.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.66B
$11.3M 0.82%
87,818
-18,596
-17% -$1.88M
KDMN
27
DELISTED
Kadmon Holdings, Inc.
KDMN
$10.7M 0.77%
2,368,958
-240,800
-9% -$881K
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$4.83B
$10.2M 0.74%
922,700
– –
MDCO
29
PUT
DELISTED
Medicines Co
MDCO
$9.34M 0.67%
+110,000
New +$7.34M
TGTX icon
30
TG Therapeutics
TGTX
$8.58B
$9.01M 0.65%
811,292
-922,336
-53% -$7.01M
CALA
31
DELISTED
Calithera Biosciences, Inc
CALA
$8.33M 0.6%
72,941
+24,698
+51% +$1.86M
DERM
32
DELISTED
Dermira, Inc.
DERM
$8.27M 0.6%
545,466
-444,702
-45% -$3.84M
ALXN
33
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$8.11M 0.58%
+75,000
New +$8.02M
CHMA
34
DELISTED
Chiasma, Inc. Common Stock
CHMA
$8.09M 0.58%
1,630,221
– –
XLRN
35
DELISTED
Acceleron Pharma
XLRN
$7.8M 0.56%
147,032
-261,230
-64% -$11.9M
ITRM
36
DELISTED
Iterum Therapeutics
ITRM
$7.77M 0.56%
115,101
– –
ARQL
37
DELISTED
Arqule Inc
ARQL
$7.73M 0.56%
387,469
-5,918
-2% -$68.6K
BCRX icon
38
BioCryst Pharmaceuticals
BCRX
$2.37B
$7.42M 0.53%
2,151,164
+1,634,430
+316% +$4.11M
ETTX
39
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$5.87M 0.42%
1,180,178
– –
OTIC
40
DELISTED
Otonomy, Inc.
OTIC
$5.8M 0.42%
1,515,629
+77,664
+5% +$190K
SGEN
41
DELISTED
Seagen Inc. Common Stock
SGEN
$5.71M 0.41%
+50,000
New +$5.3M
FTSV
42
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$5.46M 0.39%
138,643
-380,655
-73% -$6.11M
ZYME icon
43
Zymeworks
ZYME
$1.68B
$4.89M 0.35%
107,552
-80,886
-43% -$2.94M
FOLD
44
DELISTED
Amicus Therapeutics
FOLD
$4.63M 0.33%
475,330
-247,644
-34% -$2.27M
XBIT icon
45
XBiotech
XBIT
$69.2M
$4.5M 0.32%
240,995
-117,668
-33% -$1.52M
ORTX
46
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.9M 0.28%
28,341
– –
FOMX
47
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.87M 0.28%
1,162,176
-37,078
-3% -$118K
APLT
48
DELISTED
Applied Therapeutics
APLT
$3.68M 0.27%
134,825
-7,179
-5% -$123K
ACRS icon
49
Aclaris Therapeutics
ACRS
$730M
$3.61M 0.26%
1,911,573
– –
DRNA
50
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.51M 0.25%
159,512
-183,243
-53% -$3.69M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2019 Portfolio in Review

As of Q4 2019, Sofinnova Investments held 81 positions worth $1.39B, up 25% from $1.11B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments withdrew a net $93.3M in Q4 2019, closing 22 positions and reducing 17 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $46.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 88% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Galera Therapeutics, Inc. Common Stock worth $40.6M.

  • Sofinnova Investments's largest Q4 2019 buy was Galera Therapeutics, Inc. Common Stock: 3,083,712 shares worth $40.6M.
  • Sofinnova Investments added most to BioMarin Pharmaceuticals in Q4 2019, an estimated $27M increase.
  • Sofinnova Investments's biggest Q4 2019 reduction was Acceleron Pharma, cutting an estimated $11.9M.
  • Sofinnova Investments fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $46.7M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $1.39B portfolio in Q4 2019.
  • Sofinnova Investments opened 10 new positions and closed 22 in Q4 2019.
  • Sofinnova Investments's portfolio value rose 25% quarter-over-quarter to $1.39B.

Based on Sofinnova Investments's 13F filing for Q4 2019, filed 14 Feb 2020.